Predict your next investment

Corporate Venture
bracepharma.com

See what CB Insights has to offer

Investments

29

Portfolio Exits

7

Service Providers

1

About Brace Pharma Capital

Brace Pharma is the U.S. investment company of EMS, Brazil's largest pharmaceutical company. Brace Pharma invests in companies developing innovative therapies for life threatening diseases with insufficient treatment options. Brace Pharma's partnership model funds late stage clinical programs with the potential for commercialization within three to five years.

Brace Pharma Capital Headquarters Location

155 Gibbs Street Suite 506

Rockville, Maryland, 20850,

United States

240-403-7153

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Brace Pharma Capital News

New York City’s Turnstone Biologics secures US $80M Series D

Jul 21, 2021

On: CPE News (7/21/2021) – Turnstone Biologics Corp., a Delaware company, has closed an $80 million Series D financing co-led by PFM Health Sciences and Point72. Additional new investors Eventide Asset Management, Surveyor Capital (a Citadel company), Ridgeback Capital Investments, Takeda Ventures Inc., CaaS Capital, JM Family Enterprises, Inc., Northleaf Capital Partners, 404 Bio and an undisclosed investor were joined by existing investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital. The financing closed in late June. New York City based Turnstone intends to use new funding to advance its pipeline of programs from its oncolytic virus and TIL therapy platforms. Turnstone Biologics have raised over US $172 million in venture capital financing to date. Initially founded in Ottawa by Dr. John Bell (The Ottawa Hospital and University of Ottawa), Dr. Brian Lichty (McMaster University) and Dr. David Stojdl (Children’s Hospital of Eastern Ontario and University of Ottawa), Turnstone Biologics is a privately held clinical stage biotech company developing breakthrough cancer immunotherapies by advancing two leading platforms, both independently and in combination, that drive innate and adaptive tumor immunity to provide benefit to the millions of cancer patients underserved by current treatment options. In addition to New York City head office, Turnstone Biologics continues to maintain office in Ottawa and has an additional office in San Diego, California. photo credit: Turnstone Biologics Turnstone Biologics Raises $80 Million Series D Financing Proceeds to support continued development of Turnstone’s pipeline of oncolytic virus and TIL therapy candidates July 21, 2021 06:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, today announced the successful completion of an $80 million Series D financing co-led by PFM Health Sciences and Point72. Additional new investors Eventide Asset Management, Surveyor Capital (a Citadel company), Ridgeback Capital Investments, Takeda Ventures Inc., CaaS Capital, JM Family Enterprises, Inc., Northleaf Capital Partners, 404 Bio and an undisclosed investor were joined by existing investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital. “Turnstone is developing next-generation medicines in two of the most clinically validated fields of immunotherapy for solid tumors,” said Sammy Farah, Ph.D., MBA, President and CEO at Turnstone. “This oversubscribed financing will allow us to advance our vision to benefit millions of cancer patients underserved by current treatment options. We are delighted to welcome PFM Health Sciences, Point72 and additional new investors to Turnstone, and we are grateful for the steadfast support of our existing syndicate.” Proceeds from the financing will be used to advance Turnstone’s pipeline of programs from its oncolytic virus and TIL therapy platforms. Turnstone’s lead oncolytic virus candidate, RIVAL-01/TAK-605, is currently in the dose escalation stage of a Phase 1/2a clinical study in solid tumors conducted in collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). The product is derived from the Company’s proprietary vaccinia virus platform that has been engineered for enhanced immune-stimulation and tumor cell selectivity, large transgene carrying capacity for local expression of encoded therapeutics, and with flexibility for both intratumoral and intravenous delivery. Turnstone’s lead TIL therapy candidate, TIDAL-01, is expected to enter clinical development by early next year. The program builds on clinically validated treatment protocols while enriching for the most relevant T-cells for tumor eradication, preserving broad antigen diversity, and minimizing time to treatment for patients, with the ultimate goal of extending the benefit of TIL therapy across a wider range of solid tumor types. Concurrent with the financing, Santhosh Palani, Ph.D., CFA, Partner at PFM Health Sciences, will join the Company’s Board of Directors. “The addition of the TIL therapy platform to Turnstone’s existing viral immunotherapy creates a significant strategic advantage for the Company,“ said Dr. Palani. “Turnstone’s TIL programs represent the most direct approach to advance the field as there is strong clinical evidence that selection of tumor reactive T-cells can drive better patient outcomes. The enhanced benefit and curative potential that Turnstone can uniquely bring by combining viral immunotherapy with TILs to solve challenges associated with solid tumors, drives yet another layer of excitement.” About Turnstone Biologics Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading platforms, both independently and in combination, that drive innate and adaptive tumor immunity to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone’s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity and local expression of encoded therapeutics. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01/TAK-605, which is being developed under a global collaboration with Takeda. The novel TIL therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing time to treatment for patients. Turnstone is expecting the lead TIL therapy candidate, TIDAL-01, to enter the clinic by early 2022. For more information, please visit www.turnstonebio.com, and follow Turnstone on LinkedIn. Contacts

Brace Pharma Capital Investments

29 Investments

Brace Pharma Capital has made 29 investments. Their latest investment was in Antiva Biosciences as part of their Series D on November 11, 2021.

CBI Logo

Brace Pharma Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/2/2021

Series D

Antiva Biosciences

$31M

No

6

7/14/2021

Series D

Turnstone Biologics

$80M

Yes

18

2/11/2021

Series C

Pipeline Therapeutics

$80M

No

20

8/25/2020

Series C

Subscribe to see more

$99M

Subscribe to see more

10

8/12/2020

Unattributed VC - V

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/2/2021

7/14/2021

2/11/2021

8/25/2020

8/12/2020

Round

Series D

Series D

Series C

Series C

Unattributed VC - V

Company

Antiva Biosciences

Turnstone Biologics

Pipeline Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$31M

$80M

$80M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

18

20

10

10

Brace Pharma Capital Portfolio Exits

7 Portfolio Exits

Brace Pharma Capital has 7 portfolio exits. Their latest portfolio exit was ReViral on April 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/7/2022

Acquired

$99M

9

6/12/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/28/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/21/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/29/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/7/2022

6/12/2020

3/28/2019

6/21/2018

3/29/2018

Exit

Acquired

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

9

10

10

10

10

Brace Pharma Capital Service Providers

1 Service Provider

Brace Pharma Capital has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Brace Pharma Capital Team

1 Team Member

Brace Pharma Capital has 1 team member, including current Chief Executive Officer, President, Vinzenz Ploerer.

Name

Work History

Title

Status

Vinzenz Ploerer

EMS, and Sandoz

Chief Executive Officer, President

Current

Name

Vinzenz Ploerer

Work History

EMS, and Sandoz

Title

Chief Executive Officer, President

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.